Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dargistotug · M-6223

Monoclonal antibody · Antagonist of TIGIT · developed by EMD Serono Research & Development Institute

Phase 2 Most advanced trial
1 Registered trials

What is Dargistotug?

Dargistotug is a human IgG1 monoclonal antibody that binds TIGIT, an immune checkpoint inhibitor on T-lymphocytes and NK cells. By blocking TIGIT, it prevents inhibitory signaling and enhances costimulatory CD226 signaling, activating immune responses against cancer. It is studied in locally advanced or metastatic urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
M-6223
Drug type
Monoclonal antibody
Targets
TIGIT, CD112 (CADM1) (secondary target), CD155 (PVR) (secondary target), CD226 (secondary target)
Mechanism
Antagonist of TIGIT
Pathways
immune checkpoint inhibition, T-cell activation, NK cell activation
Therapy area
Oncology
Developer
EMD Serono Research & Development Institute, Inc.
In trials of
GILD, MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4O3LRM3I5J

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05327530 Phase 2 Locally Advanced or Metastatic Urothelial Carcinoma Active not recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced or Metastatic Urothelial Carcinoma

Other drugs acting on TIGIT

BMS-986442 Phase 1 Domvanalimab Phase 2 Rilvegostomig Phase 3 TAB006 Phase 1 Tiragolumab Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.